沃华医药(002107) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 217,836,836.34, representing a 1.17% increase compared to CNY 215,317,031.37 in the same period last year[5]. - Net profit attributable to shareholders increased by 136.47% to CNY 22,859,812.88 from CNY 9,667,223.23 year-on-year[5]. - The net profit after deducting non-recurring gains and losses rose by 168.15% to CNY 22,057,608.04 compared to CNY 8,225,848.56 in the previous year[5]. - Total operating revenue for the current period is $217.84 million, an increase from $215.32 million in the previous period, representing a growth of approximately 1.16%[19]. - Operating profit for the current period is $26.10 million, significantly up from $10.65 million in the previous period, marking an increase of approximately 144.61%[20]. - Net profit for the current period is $22.11 million, compared to $8.76 million in the previous period, reflecting a growth of around 151.36%[20]. - Basic and diluted earnings per share both increased to $0.04 from $0.02, a 100% increase[21]. Assets and Liabilities - The company's total assets increased by 3.45% to CNY 1,019,778,595.34 from CNY 985,730,497.97 at the end of the previous year[5]. - Current assets rose to CNY 585,761,028.62, up from CNY 543,118,402.76, indicating an increase of about 7.9%[15]. - Cash and cash equivalents increased to CNY 404,025,624.09 from CNY 344,774,257.71, representing a growth of approximately 17.2%[15]. - Total liabilities increased to CNY 278,652,215.28 from CNY 262,796,323.54, reflecting a growth of about 6.0%[17]. - The company's equity attributable to shareholders rose to CNY 720,228,118.28 from CNY 697,368,305.40, marking an increase of approximately 3.3%[17]. - The company's retained earnings increased to CNY 96,746,369.31 from CNY 73,886,556.43, representing a growth of about 31.0%[17]. - The company’s non-current liabilities decreased to CNY 19,630,708.08 from CNY 20,506,490.20, reflecting a decline of about 4.3%[17]. Cash Flow - Cash flow from operating activities decreased by 11.60% to CNY 48,166,664.21 compared to CNY 54,487,330.32 in the previous year[5]. - Cash flow from operating activities generated a net amount of $48.17 million, down from $54.49 million in the previous period, a decrease of about 11.56%[22]. - The company reported a significant increase in investment cash flow, with a net inflow of CNY 14,591,250.00 compared to a net outflow of CNY 119,485.74 in the same period last year, marking a 12,311.71% change[9]. - The company recorded a net cash inflow from investment activities of $14.59 million, compared to a net outflow of $119.49 thousand in the previous period[23]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,476, with the largest shareholder holding 50.27% of the shares[10]. Expenses - Research and development expenses increased to $10.27 million from $8.52 million, an increase of about 20.54%[20]. - The company reported a tax expense of $3.98 million, up from $2.01 million, indicating a rise of approximately 97.56%[20]. Other Financial Metrics - The weighted average return on equity improved to 3.23%, up from 1.19% in the same period last year, reflecting better profitability[5]. - The company's basic and diluted earnings per share both doubled to CNY 0.04 from CNY 0.02 in the previous year[5]. - The company experienced a 32.02% increase in prepaid accounts due to higher material procurement payments during the reporting period[9]. - Inventory decreased to CNY 98,562,497.96 from CNY 107,134,043.15, indicating a decline of approximately 8.5%[15]. - The company reported a decrease in contract liabilities to CNY 2,364,396.69 from CNY 6,850,350.20, indicating a decline of approximately 65.5%[16].